Novavax Inc. logo

Novavax Inc. (NVAX)

Market Closed
4 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
10. 19
-0.01
-0.098%
$
1.8B Market Cap
- P/E Ratio
- Div Yield
5.23M Volume
-4.28 Eps
$ 10.2
Previous Close
Add Transaction
Day Range
10.1 10.59
Year Range
6.13 11.97
Want to track NVAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider

Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Novavax (NVAX) closed at $12.06, indicating a +1.34% shift from the previous trading day.

Zacks | 1 year ago
Novavax's Second Act: How a Fallen COVID Star Could Rise from the Ashes

Novavax's Second Act: How a Fallen COVID Star Could Rise from the Ashes

During May and June, Novavax (NASDAQ: NVAX ) shares appeared to be making a major comeback. At the time, news of a partnership deal with pharma firm Sanofi (NASDAQ: SNY ), as well as another positive development, were driving Novavax stock “to the moon.

Investorplace | 1 year ago
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.

Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.

Nvidia (NASDAQ: NVDA ) has become the face of artificial intelligence and its stock has responded in kind. Shares are up 200% over the past year and over 800% since the release of ChatGPT, which sparked an AI tsunami.

Investorplace | 1 year ago
Where Will Novavax Be in 1 Year?

Where Will Novavax Be in 1 Year?

Novavax recently made a move that improved its financial position and prospects. The biotech has two pivotal clinical trials in the works.

Fool | 1 year ago
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know

Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know

Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.

Zacks | 1 year ago
Meme Stock or Vaccine Stock? Novavax's Identity Crisis and Why It Matters for Investors

Meme Stock or Vaccine Stock? Novavax's Identity Crisis and Why It Matters for Investors

Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ: NVAX ) the green light to target a specific Covid-19 variant.

Investorplace | 1 year ago
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe

Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe

Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.

Zacks | 1 year ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 year ago
Is Novavax Stock A Buy On A Vaccines Rally Following Bullish Moderna News?

Is Novavax Stock A Buy On A Vaccines Rally Following Bullish Moderna News?

Is Novavax stock a buy after vaccine stocks surged on bullish news from Moderna? Is NVAX stock a buy right now?

Investors | 1 year ago
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note

Novavax (NVAX) Ascends While Market Falls: Some Facts to Note

In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.

Zacks | 1 year ago
3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment

3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment

It was not long ago that Novavax (NASDAQ: NVAX ) was among the stocks with high short interest. The stock had been trending lower for an extended period.

Investorplace | 1 year ago
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.

Zacks | 1 year ago
Loading...
Load More